BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics (GPCR)Structure TherapeuticsConference / presentation

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful

Related news

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

ACRSAclaris Therapeutics2026-05-28 12:30 EST

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

CUECue Biopharma Inc2026-05-21 20:05 EST

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

IMMPImmutep Limited2026-07-24 12:00 EST

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Stock data

Close
52.62 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States